Literature DB >> 18806764

LDL apheresis in the treatment of non-arteritic ischaemic optic neuropathy: a 6-month follow-up study.

S Guerriero1, G Giancipoli, A Cantatore, G Sacco, P Brescia, M T Saliani, A Ramunni.   

Abstract

PURPOSE: Verify the recovery of visual capacity after the administration of a combination of LDL apheresis (LA) and conventional therapy (CT). Design, prospective and interventional case series.
METHODS: 20 patients affected by NAION were randomly subdivided into two groups of 10 patients (Group 1 and Group 2). Group 1 underwent three sessions of LA associated with CT, whereas group 2 received only CT. At discharge and at the 6 months follow-up visit, assessment in both groups was made of the best corrected visual acuity (BCVA) and the computerised visual field (CVF), comparing the findings with those at admission in each patient.
RESULTS: Only the mean deviation (MD) at CVF was statistically improved in group 1 as compared with group 2 at discharge, judged against the values at admission (-11.08+/-6.51 vs -16.53+/-10.03, P=0.039; -17+/-5.24 vs -14.14+/-9.42, respectively). However, this increase was not confirmed at 6 months (-16.83+/- -10.72, group 1; -13.56+/-3.60 group 2).
CONCLUSION: In NAION, LA induced a short term improvement in the MD, but by 6 months this had disappeared.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806764     DOI: 10.1038/eye.2008.287

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  2 in total

1.  Therapeutic apheresis in peripheral and retinal circulatory disorders.

Authors:  Alfonso Ramunni; Paola Brescia; Giuseppina De Fino; Giovanni Piscopo; Loreto Gesualdo
Journal:  Clin Res Cardiol Suppl       Date:  2012-06

Review 2.  Efficacy of Treatments in Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.

Authors:  Krisztina Lantos; Zsuzsa Réka Dömötör; Nelli Farkas; Szabolcs Kiss; Zsolt Szakács; András Garami; Gábor Varga; László Lujber; Reem Kanaan; Péter Hegyi; Gergely Fehér; Valéria Gaál
Journal:  Int J Environ Res Public Health       Date:  2022-02-26       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.